Von Hippel-Lindau Tumor Suppressor Protein
"Von Hippel-Lindau Tumor Suppressor Protein" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A ubiquitin-protein ligase that mediates OXYGEN-dependent polyubiquitination of HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT. It is inactivated in VON HIPPEL-LINDAU SYNDROME.
| Descriptor ID |
D051794
|
| MeSH Number(s) |
D08.811.464.938.750.875 D12.776.624.776.865
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Von Hippel-Lindau Tumor Suppressor Protein".
Below are MeSH descriptors whose meaning is more specific than "Von Hippel-Lindau Tumor Suppressor Protein".
This graph shows the total number of publications written about "Von Hippel-Lindau Tumor Suppressor Protein" by people in this website by year, and whether "Von Hippel-Lindau Tumor Suppressor Protein" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2012 | 1 | 0 | 1 |
| 2013 | 0 | 1 | 1 |
| 2014 | 1 | 1 | 2 |
| 2017 | 3 | 0 | 3 |
| 2018 | 1 | 1 | 2 |
| 2020 | 2 | 1 | 3 |
| 2021 | 0 | 2 | 2 |
| 2023 | 0 | 2 | 2 |
| 2025 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Von Hippel-Lindau Tumor Suppressor Protein" by people in Profiles.
-
Update on Surveillance in Von Hippel-Lindau Disease. Clin Cancer Res. 2025 Jun 13; 31(12):2271-2277.
-
Guidelines for surveillance of patients with von Hippel-Lindau disease: Consensus statement of the International VHL Surveillance Guidelines Consortium and VHL Alliance. Cancer. 2023 10 01; 129(19):2927-2940.
-
Developing a disease-specific annotation protocol for VHL gene curation using Hypothes.is. Database (Oxford). 2023 01 06; 2023.
-
Therapeutically actionable signaling node to rescue AURKA driven loss of primary cilia in VHL-deficient cells. Sci Rep. 2021 05 17; 11(1):10461.
-
Hypoxia-inducible factor activity promotes antitumor effector function and tissue residency by CD8+ T cells. J Clin Invest. 2021 04 01; 131(7).
-
The Daam2-VHL-Nedd4 axis governs developmental and regenerative oligodendrocyte differentiation. Genes Dev. 2020 09 01; 34(17-18):1177-1189.
-
Ancestry-specific predisposing germline variants in cancer. Genome Med. 2020 05 29; 12(1):51.
-
Identification of a new aggressive axis driven by ciliogenesis and absence of VDAC1-?C in clear cell Renal Cell Carcinoma patients. Theranostics. 2020; 10(6):2696-2713.
-
Bexarotene - a novel modulator of AURKA and the primary cilium in VHL-deficient cells. J Cell Sci. 2018 12 14; 131(24).
-
VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma. Science. 2018 07 20; 361(6399):290-295.